Stocklore

HCA Healthcare, Inc. (HCA)

Biotech & Health · US stock

What changed in recent filings

  • Institutions — 7 new · 1 added13F · as of end of 2026 Q2

What changed in recent SEC filings — factual, not a buy/sell recommendation.

Institutions holding HCA Healthcare, Inc.

How many of the institutions we track reported holding this stock, quarter by quarter.

max 8
2019 Q1 · 42019 Q2 · 22019 Q3 · 32019 Q4 · 42020 Q1 · 62020 Q2 · 72020 Q3 · 72020 Q4 · 72021 Q1 · 62021 Q2 · 52021 Q3 · 62021 Q4 · 32022 Q1 · 42022 Q2 · 72022 Q3 · 52022 Q4 · 42023 Q1 · 52023 Q2 · 62023 Q3 · 52023 Q4 · 62024 Q1 · 42024 Q2 · 32024 Q3 · 22024 Q4 · 32025 Q1 · 22025 Q2 · 22025 Q3 · 22025 Q4 · 22026 Q1 · 22026 Q2 · 8
19 Q122 Q326 Q2

2019 Q1: 4 → 2026 Q2: 8 institutions

Counts the 52 institutions we track that reported holding this stock — their full reported holdings, not just the largest positions. Not the total number of institutional holders in the US. Figures are as of quarter-end and disclosed up to 45 days later. Descriptive only — not investment advice.

Which institutions hold HCA Healthcare, Inc.

Institutions we track that reported holding this stock in their most recent 13F.

  • Bridgewater Associates0.33% of portfolio · since 2020 Q1
  • Capital World Investors0.09% of portfolio · held as of 2026 Q2 or earlier
  • National Pension Service (Korea)0.15% of portfolio · held as of 2026 Q2 or earlier
  • Caisse de depot (Quebec)0.04% of portfolio · held as of 2026 Q2 or earlier
  • Harris Associates (Oakmark)0.08% of portfolio · held as of 2026 Q2 or earlier
  • Pzena Investment Management0.11% of portfolio · held as of 2026 Q2 or earlier
  • Blackstoneunder 0.01% of portfolio · held as of 2026 Q2 or earlier
  • Temasek Holdings (Singapore)New this quarter0.01% of portfolio · since 2026 Q2

Based on 13F filings — quarter-end holdings, disclosed up to 45 days later. Holding a stock is a fact we report, not a recommendation to buy or sell.

Company overview

The largest US private hospital chain, operating over 180 hospitals and more than 2,000 outpatient facilities.

What is the Biotech & Health sector?

Pharma, biotech, and medical devices. Driven by trial-result events.

HCA Healthcare, Inc. is classified under the Biotech & Health sector. See peers below.

ETFs holding HCA Healthcare, Inc.

Per SEC N-PORT · 2026-06-30 · by weight · factual

XLVState Street(R) Health Care Select Sector SPDR(R) ETF
1.05%
VTVVANGUARD VALUE INDEX FUND
0.23%
RSPInvesco S&P 500 Equal Weight ETF
0.16%
SPY
0.09%
VOOVANGUARD 500 INDEX FUND
0.09%
IVViShares Core S&P 500 ETF
0.09%
VTIVANGUARD TOTAL STOCK MARKET INDEX FUND
0.08%
ITOTiShares Core S&P Total U.S. Stock Market ETF
0.08%

HCA on Stocklore

  • Revenue by segmentsegment weights verified from SEC filings, YoY changes, growth drivers and concentration
  • Financials & earnings quality6 metrics (FCF conversion, ROIC, net debt, etc.) to gauge profit quality
  • 13F institutional holdingsholdings and weight changes of major institutions (45-day delay)
  • Sector-relative metricsValuation and growth compared with the Biotech & Health average
See full HCA analysis →

Peers · Biotech & Health

HCA FAQ

What is HCA Healthcare, Inc. (HCA)?

The largest US private hospital chain, operating over 180 hospitals and more than 2,000 outpatient facilities.

What sector is HCA Healthcare, Inc. in?

HCA Healthcare, Inc. is classified under Biotech & Health. Pharma, biotech, and medical devices. Driven by trial-result events.

Where can I analyze HCA Healthcare, Inc. (HCA) stock?

On Stocklore you can see HCA's financials & earnings quality, 13F institutional holdings, and sector-relative metrics in one place. This page is for information and tools — not a buy/sell recommendation.

Data sources: SEC EDGAR (financials & filings), 13F (institutional holdings, as of quarter-end), market data. This page is for information and analysis tools — it does not recommend buying or selling any security. Investment decisions and responsibility are your own.

Not an investment adviser and not personalized investment advice; not a discretionary management service. No trade recommendations, no target prices, no execution or brokerage. We do not recommend or guarantee any purchase, sale, or returns. Investment decisions and their outcomes are your own.

Stocklore · CEO Lee Seung-jae · Business reg. no. 764-36-01607 · E-commerce permit 2026-Jeonju Wansan-0476 · Tel +82-70-7954-4939 · S120, Rm 302, 3F, 21 Jungsanjungang-ro, Wansan-gu, Jeonju, Jeonbuk, Korea